Clinical trial
Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
NCT01872936 is registered in ClinicalTrials.gov with Santaris Pharma A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
- Lead sponsor
- Santaris Pharma A/S
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- June 30, 2013
- Completion date
- January 31, 2015
- Enrollment
- 20 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.